Genetic markers in newly diagnosed myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at certain genetic changes in patients newly diagnosed with multiple myeloma to understand how they affect the disease. It may help doctors better predict outcomes and tailor treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with multiple myeloma.
- You must not have received any treatment for multiple myeloma yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
This study collects information and samples from people with multiple myeloma or related blood disorders to understand why the disease affects people differently. Researchers will use this information to develop better, personalized treatment approaches.
This trial studies tissue samples from people with a specific genetic change in their myeloma cells. It aims to better understand this type of myeloma to improve future treatment.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This study looks at different ways to treat people who are newly diagnosed with multiple myeloma that has a change in chromosome 1 (+1q). The goal is to find the best treatment plan based on each person's risk level.
Hear when a new Multiple Myeloma, Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.